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Abstract 
Optical imaging has emerged as a powerful modality for studying molecular recognitions and 
molecular imaging in a noninvasive, sensitive, and real-time way. Some advantages of optical im-
aging include cost-effectiveness, convenience, and non-ionization safety as well as complementa-
tion with other imaging modalities such as positron emission tomography (PET), single-photon 
emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Over the past 
decade, considerable advances have been made in tumor optical imaging by targeting integrin 
receptors in preclinical studies. This review has emphasized the construction and evaluation of 
diverse integrin targeting agents for optical imaging of tumors in mouse models. They mainly in-
clude some near-infrared fluorescent dye-RGD peptide conjugates, their multivalent analogs, and 
nanoparticle conjugates for targeting integrin αvβ3. Some compounds targeting other integrin 
subtypes such as α4β1 and α3 for tumor optical imaging have also been included. Both in vitro and 
in vivo studies have revealed some promising integrin-targeting optical agents which have further 
enhanced our understanding of integrin expression and targeting in cancer biology as well as re-
lated anticancer drug discovery. Especially, some integrin-targeted multifunctional optical agents 
including nanoparticle-based optical agents can multiplex optical imaging with other imaging mo-
dalities and targeted therapy, serving as an attractive type of theranostics for simultaneous imaging 
and targeted therapy. Continued efforts to discover and develop novel, innovative integrin-based 
optical agents with improved targeting specificity and imaging sensitivity hold great promises for 
improving cancer early detection, diagnosis, and targeted therapy in clinic. 
Key  words:  optical  imaging,  near-infrared  fluorescence;  multivalent  RGD  peptides,  multifunc-
tional probes, nanoparticle-based optical agents. 
1. Introduction 
Optical  imaging  for  cancer  research  Cancers  con-
tinue to threaten human health and life even with the 
availabilities  of  chemotherapy,  radiotherapy,  and 
surgery as well as various methods for detection and 
diagnosis. The challenges with cancer early detection, 
diagnosis,  effective  therapy,  and  even  prevention 
have spurred the discovery and development of new 
technologies and approaches for cancer research and 
drug  discovery.  The  past  decade  has  witnessed  the 
burgeoning of optical imaging and its wide applica-
tions in biomedicines such as genomics, proteomics, 
cell biology, and drug discovery. Optical imaging has 
emerged  as  a  real-time,  sensitive,  and  noninvasive 
modality  for  visualization,  localization,  and  meas-
urement  of  bioactive  molecules,  molecular  recogni-
tions, and molecular processes in vivo. Even though 
optical imaging still cannot compete with PET, MRI, 
and CT in clinical applications now, the advantages of Theranostics 2011, 1 
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optical  imaging  in  convenient  use,  sensitivity,  cost 
effectiveness,  and  non-ionization  safety  have  espe-
cially made it a spearhead among the traditional im-
aging modalities for molecular imaging in preclinical 
studies. Optical imaging of receptors, enzymes, gene 
expression, live cells, and tumors in vitro and in vivo 
has deepened our understanding of disease progres-
sion and therapeutic response at the molecular, cell, 
tissue,  and  whole-animal  levels.  Therefore,  optical 
imaging holds great promise for cancer early detec-
tion, diagnosis, prevention and therapy as introduced 
in many excellent review articles [1-14]. 
Optical imaging methods for in vivo tumor imaging 
Over the past years, different kinds of optical imaging 
techniques have been developed for  biomedical ap-
plications. They include various microscopy methods 
such as confocal microscopy, two-photon microscopy, 
and  coherent  anti-Stokes  Raman  scattering  (CARS) 
microscopy for in vitro and ex vivo applications as well 
as  several  methods  for  in vivo  applications  such  as 
bioluminescence imaging, fluorescence imaging, dif-
fused optical tomography, and optical coherence to-
mography. Various techniques can be used in com-
bination,  either  simultaneously  or  sequentially,  to 
provide  complementary  information  from  the  same 
cells, tissues, organs, or animals [10]. Among them, 
both  fluorescence  and  bioluminescence  imaging 
techniques have found wide applications for in vivo 
tumor optical imaging in mouse models and  afford 
convenient, frequent visualization and measurement 
of  tumor  biomarkers  in  a  real  time,  sensitive,  and 
noninvasive  way.  It  also  can  allow  for  longitudinal 
detection of disease progression and therapeutic re-
sponse  in  the  same  animals  so  as  to  minimize  the 
subject–to-subject  variability  and  reduce  the  animal 
number  required  by  a  traditional  method.  Im-
portantly, such in vivo studies are very valuable for 
bridging the  gap between  in vitro (cell/tissue level) 
and in vivo (the whole animal) studies and facilitating 
preclinical and further translational studies.  
Bioluminescence imaging (BLI) is typically based 
on the ATP- and O2-dependent enzymatic conversion 
of  exogenous  luciferin  to  oxyluciferin  by  luciferase 
within living cells. The reaction can produce photons 
with a broad red and far-red emission spectrum of a 
peak  around  560  nm  which  can  be  detected  by  a 
highly sensitive charge-coupled device (CCD) camera 
at 10–12 min after intraperitoneal injection of luciferin. 
The  bioluminescence  can  last  over  60  min  in  mice, 
allowing for the recording of multiple images of dis-
ease progression and therapeutic response based on 
the changes in the number of cells with luciferase ex-
pression or transcriptional activity. BLI has allowed 
quantitative  measurements  of  tumor  burden,  treat-
ment response, immune cell trafficking, and detection 
of gene transfer. Spatiotemporal information can be 
rapidly  obtained  in  the  context  of  whole  biological 
systems in vivo, which can accelerate the development 
of experimental therapeutic strategies [13, 15]. 
Fluorescence imaging is to excite certain fluor-
ophores in a living system by using external light and 
detect  fluorescence  emission  with  a  sensitive  CCD 
camera. The fluorophores  can be endogenous mole-
cules  (such  as  collagen  or  hemoglobin),  exogenous 
fluorescent molecules such as green fluorescent pro-
tein (GFP) or small synthetic optical contrast agents. 
Compared to in vitro fluorescence microscope, in vivo 
fluorescence imaging is a complex process affected by 
many factors. One great limitation of in vivo fluores-
cence imaging is from light attenuation and scattering 
by adjacent living tissues. Light in the near infrared 
(NIR)  window  (650-900  nm)  instead  of  visible  light 
can improve the light penetration [13, 16]. It can also 
minimize the autofluorescence of some endogenous 
absorbers such as hemoglobin, water, and lipids. In a 
whole mouse illumination experiment, photon counts 
in the NIR range (670 nm) are about 4 orders of mag-
nitude  higher  compared  to  those  in  the  green  light 
range  (530  nm)  under  similar  conditions. 
Near-infrared fluorescence imaging has provided an 
effective  solution  for  improving  the  imaging  depth 
along  with  sensitivity  and  specificity.  Therefore, 
fluorophores emitted at the NIR region are important 
for successful in vivo optical imaging and future clin-
ical applications. 
NIR  fluorophores  and  targeted  delivery  Different 
kinds of fluorescent fluorophores have been discov-
ered for biomedical imaging [1, 7, 16]. They include: 1) 
small synthetic fluorophores such as cyanine fluoro-
phores (including benzoxazole, benzothaizole, indol-
yl,  2-quinoline  or  4-quinoline  cyanine  analogs), 
tetrapyrrol chromophores (such as porphyrins, chlo-
rins,  benzochlorins,  bacteriochlorin  and  phthalocya-
nines), rare earth metal chelates (such as terbium and 
europium  complexes),  and  xanthenes  dyes  (such  as 
fluorescein-  and  rhodamine-type  fluorophores);  2) 
synthetic fluorescent nanoparticles such as semicon-
ductor nanocrystals, i.e. quantum dots (QDs) [17] and 
fluorescent viral nanoparticles [18]; and 3) fluorescent 
biological nanoparticles such as GFP and many other 
fluorescent  proteins  [19-20].  Among  them,  the  NIR 
fluorescent fluorophores most commonly used for in 
vivo imaging are some synthetic cyanine analogs such 
as commercially available Cy5, Cy5.5, Cy7, Cy7.5, and 
their  analogs  of  different  conjugation  groups  and 
linkers (Fig. 1). They have medium to high extinction 
coefficients with emission spectra in the NIR range. Theranostics 2011, 1 
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They can be synthesized in a straightforward manner 
and  modified  to  have  different  physicochemical 
properties  such  as  hydrophilicity,  absorption,  and 
emission wavelength for different applications. They 
have suitable photo- and chemical stability desirable 
for chemical modification as well as in vitro and in vivo 
applications.  Their  characteristic  NIR  fluorescent 
properties can usually be retained after conjugation 
with proteins, peptides, and other bioactive materials 
for in vivo imaging. Noteworthy, a known carbocya-
nine analog indocyanine green (ICG) has been used as 
nonspecific  blood  flow  tracer  in  human  studies  for 
cancer detection. It is the first dye used in optical im-
aging of tumors both in animal studies and for pa-
tients  [7,  21-25].  Therefore,  its  well-established 
bio-safety  profile  may  facilitate  the  translational 
studies and clinic applications of such a type of cya-
nine-labeled  compounds.  In  addition  to  cyanine 
fluorophores,  QDs  represent  an  attractive  class  of 
fluorescent  nanoparticle  probes  for  in  vivo  fluores-
cence imaging. They usually have a core/shell struc-
ture of 2-8 nm in diameter with size-dependent fluo-
rescence  emission.  Their  unique  optical  properties 
include high absorbance, high quantum yield, narrow 
emission bands, large Stokes shifts, and high photo-
bleaching resistance. QDs can be excited with a single 
wavelength  to  give  emissions  at  several  different 
wavelengths for multiplex detection of multiple tar-
gets in a single experiment [17, 26]. 
 
N N
O
SO3Na NaO3S
-O3S
O
O
N
SO3Na
N N
+
O OH
+
OH O
N N
SO3
-Na+ -O3S
+ +
+ N N
+
-O3S SO3
-
O
O
N N
O
O
SO3
-
-O3S
-O3S
SO3
-
N N
Cl
SO3
-Na+ -O3S
N N
O
O
N
O
O
+
Cy5 NHS ester
N
O
O
Cy7 NHS ester
Cy5.5 NHS ester
N
O
O
ICG Cypate
IRDye®800CW NHS ester
IR820
-O3S SO3
-
N N
+
O
O
N
O
O
Cy7.5 NHS ester
SO3
-
-O3S SO3
-
-O3S
N N
O
SO3Na NaO3S
-O3S
NH
O
N O
O
SO3Na
+
IRDye®800 CW maleimide
O
O
+
 
Figure 1. Chemical structures of some representative cyanine fluorophores. 
 
 
It is ideal to have an imaging agent selectively 
homed in the tumor lesions for best imaging contrast 
and diagnostic accuracy in vivo. Nevertheless, most of 
the dyes themselves are not tumor-specific. Especial-
ly, the in vivo performance of an imaging probe can be 
complicated  by  its  interactions  with  many 
bio-molecules,  membranes  and  related  cellular  per-
meability or tissue penetration as well as pharmaco-
kinetic  process  including  absorption,  distribution, 
metabolism, and excretion (ADME). Therefore, it has 
been challenging to discover and develop an optimal 
optical imaging agent for in vivo tumor optical imag-Theranostics 2011, 1 
 
http://www.thno.org 
105 
ing. As demonstrated by many successful examples, 
some  tumor-specific  molecular  markers  and  related 
molecular  recognitions,  i.e.  ligand-receptor,  en-
zyme-substrate,  and  antibody-antigen  interactions 
may provide effective approaches for targeted deliv-
ery of therapeutic agents and imaging agents such as 
immunotoxins  and  radioimmunotherapeutics  for 
cancer  imaging  and  therapy.  Especially,  some  cell 
surface  receptors  over-expressed  by  cancer  cells 
and/or  neovascular  endothelial  cells  can  serve  as 
specific  molecular  markers  for  tumor  targeting  and 
molecular imaging [27-30]. Conjugations of some re-
ceptor ligands (such as peptides, aptamers, and anti-
bodies)  endow  an  optical  probe  with  recep-
tor-targeting and tumor-homing ability to enhance the 
optical signals from tumors and improve sensitivity 
and specificity of in vivo tumor optical imaging. Such 
receptor-targeted optical imaging agents can also be 
used to probe the receptor expressions, signal path-
ways,  functions  and  modulations,  providing  some 
meaningful  information  for  cancer  diagnosis,  early 
detection, staging, and therapeutic response as well as 
anticancer drug discovery. 
2. Integrin-Targeting Optical Agents for Tu-
mor Imaging 
The integrins are a family of heterodimeric cell 
surface  receptors  (24  subtypes)  composed  of  two 
non-covalently  bound  α-  and  β-  subunits.  They  are 
expressed  on  a  wide  variety  of  cells  to  mediate 
cell-extracellular  matrix  and  cell-cell  interactions  by 
transducing signals into the cells and out of the cells 
for regulating different cellular functions such as cell 
survival,  proliferation,  adhesion,  migration,  and  in-
vasion as well as angiogenesis, thrombosis, apoptosis, 
and differentiation in various pathological processes. 
Integrin  receptors  also  involve  complex  cross-talk 
with other signaling cascades like angiogenic growth 
factor VEGF [31], nonreceptor tyrosine kinase Src [32], 
and  chemokine  receptor  CXCR4  in  tumor  biology 
[33]. As reported by Lorger  et al. [34], activation of 
tumor  cell  integrin  αvβ3  controls  angiogenesis  and 
metastatic growth in the brain and could serve as a 
valuable target for the inhibition of brain metastasis. 
Several potent small-molecule αvβ3 antagonist-based 
RGD  compounds  have  been  studied  under  clinical 
trials for anti-angiogenesis, drug delivery, and cancer 
imaging [34]. The promising results have highly sug-
gested that integrin receptors are important targets for 
molecular imaging, drug  delivery and therapy. The 
complex structures and important functions of integ-
rins in oncology as well as the ineffectiveness of some 
antagonists in clinic have spurred further research via 
optical imaging and related discovery of novel integ-
rin-targeting ligands.  
Noteworthy,  immense  researches  have  been 
performed  by  other  noninvasive  imaging  methods 
including PET, SPECT, and MRI to demonstrate the 
integrin-targeting  for  cancer  imaging  as  described 
previously. Among many integrin-targeting molecu-
lar imaging agents, a glycosylated cyclo(RGDfK) de-
rivative i.e. [18F]galacto-RGD was the first applied in 
patients and has been successfully assessed in more 
than 100 patients so far [35-37]. The related concept of 
receptor targeting, animal models, and experimental 
results all have facilitated discovery and development 
of the integrin-tageting optical imaging agents. Over 
the  past  years,  there  are  many  reports  on  integ-
rin-targeting for in vivo tumor optical imaging. It has 
also  been  demonstrated  that  integrin  antagonists 
provide an effective way for targeted delivery of NIR 
fluorophores for tumor targeting and optical imaging. 
As  summarized  below,  different  kinds  of  integ-
rin-targeted  NIR  optical  probes  for  in  vivo  optical 
imaging have been constructed and evaluated in vitro 
and in vivo. They represent some of the most creative 
work by successful convergence of molecular design, 
synthetic chemistry, optical imaging, nuclear imaging, 
molecular  targeting,  cancer  biology,  and  nanotech-
nology.  Many  advances  in  NIR  fluorophores  have 
made it feasible to discover and develop new genera-
tions  of  integrin-targeted  optical  imaging  agents  to 
not only improve sensitivity and specificity of tumor 
imaging  but  also  provide  complementary  imaging 
information  for  cancer  diagnosis,  detection,  and 
prognosis.  Finally,  the  promising  integrin-targeted 
optical imaging probes may serve as a new type of 
targeted optical oncologic drugs for both cancer im-
aging and therapy.  
Construction  of  integrin-targeted  optical  probes: 
General considerations One underlying theme in in vivo 
optical imaging is to discover and develop novel in-
novative  receptor-targeted  optical  probes  for  cancer 
optical imaging. Such receptor-targeted optical probes 
also  have  potentials  for  both  imaging  and  therapy. 
Generally, a receptor-targeted imaging agent can be 
obtained by labeling a receptor ligand with an imag-
ing agent.  
For an optical imaging agent, it usually contains 
three components i.e. ligand, fluorophore, and linker 
as showed in Figure 2. Conjugation chemistry used is 
related  to  the  functionalities  of  the  ligand,  fluoro-
phore, and the resulting conjugate structures. Differ-
ent  fluorophores  containing  amino,  carboxylic  acid, 
and  its  active  N-hydroxysuccinimide  (NHS)  ester 
groups can be frequentlyused in the ligand conjuga-
tion.  More  specific  reactions  based  on  mercap-Theranostics 2011, 1 
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to-mercapto,  maleimide-mercapto,  and  azido-alkyne 
reactions have also been used to conjugate with some 
un-protected multifunctional ligands for the synthesis 
of complex conjugates.  
 
 
Figure  2.  Schematic  representation  of  general  recep-
tor-targeted optical agents. 
 
It is important to consider some factors in  the 
construction  of  integrin-targeting  optical  agents  as 
follows: 
1. Ligand and receptor interaction: Just like other 
receptor-targeted  imaging  agents,  it  is  important  to 
choose  an  appropriate  receptor-targeted  ligand, 
fluorophore, and linker for construction of novel in-
tegrin-targeted  optical  agents  with  optimal  receptor 
targeting activity. An ideal ligand should have spe-
cific  high  receptor  binding  affinity  and  selectivity 
with  a  receptor  of  abundant,  unique  expression  on 
tumor cells, but negligible or low expression on nor-
mal cells. The receptor binding affinity should be re-
tained or not be dramatically changed after conjuga-
tion  with  fluorophore.  Importantly,  the  receptor 
binding affinity of a ligand can be enhanced by some 
different approaches such as dimerization and mul-
timerization [38-40].  
2.  Fluorophore:  Various  types  of  fluorophores 
have been discovered for optical imaging as described 
above. Cyanine dyes such as Cy5.5 have been widely 
used for labeling ligands for optical imaging [1, 7, 12]. 
The  physicochemical  properties  especially  optical 
properties such as absorbance wavelength, emission 
wavelength,  extinction  coefficient,  fluorescence 
quantum yield, and life time are crucial for successful 
optical imaging. The molecules of many fluorophores 
such  as  cyanine  dyes  contain  a  strong  conjugated 
system consisting of some aromatic rings. It is essen-
tial  to  consider  the  impacts  of  fluorophores  on  the 
receptor binding, biological activities and in vivo per-
formance.  It  is  significant  to  exploit  the  synergistic 
effect of a fluorophore motif on the ligand-receptor 
interactions as reported by Achilefu et al. [41]. Espe-
cially, their molecular size, steric hindrance, and hy-
drophobicity may become detrimental for the biolog-
ical activities of some small molecules.  
3.  Linker:  As  an  essential  part  connecting  a 
fluorophore  and  a  ligand,  a  linker  including  its 
structural  type,  length,  hydrophilicity,  and  rigidity 
can frequently have important effects on the receptor 
targeting of a conjugate. It is reported that polyeth-
ylene glycol linker and simple oligopeptide sequence 
such as Gly-Gly-Gly used in the conjugation of a di-
meric RGDfK with DOTA showed significant effects 
on distribution, pharmacokinetics, and tumor imag-
ing [42].  
4. Molecular diversity: An optical agent can be 
further  modified  structurally  to  improve  receptor 
targeting  specificity,  minimize  nonspecific  binding 
and achieve high tumor imaging sensitivity and spec-
ificity. Molecular diversity is an important approach 
for  molecular  design  to  delineate  the  struc-
ture-activity relationship and discover novel optimal 
compounds. As described above, the structure of an 
integrin-targeted optical agent provides at least three 
points  for  molecular  diversity.  Different  kinds  of 
fluorophores  including  small  molecules  and  nano-
particles can be used in the construction of novel in-
tegrin-targeted optical imaging agents. Fluorophores 
such as cypate can be used as an optical scaffold for 
constructing novel optical agents such as some cyclic, 
divalent,  and  multivalent  analogs  [40,43]  to  further 
increase the molecular diversity. Significantly, some 
fluorescent  nanoparticles  allow  incorporations  of 
multiple  functionalities  for  simultaneous  tu-
mor-targeting, imaging, and therapy, serving as po-
tential tumor-targeted theranostic nanoparticles.  
Evaluation of integrin-targeted optical probes  Gen-
erally  speaking,  the  integrin-targeted  optical  agents 
can be evaluated in several aspects: 
1.  Physico-chemical  properties:  These  include 
optical  properties  such  as  absorption,  emission,  ex-
tinction  coefficient,  life  time,  fluorescence  quantum 
yield, and photo-stability. It is also important to de-
termine the solubility of a compound as higher lipo-
philicity may lead to more nonspecific tissue absorp-
tion [7, 16, 44]. 
2. In vitro studies: These include receptor bind-
ing, cell staining, cellular internalization, subcellular 
localization, and cytotoxicity. Fluorescence, confocal, 
and intravital microscopes are usually used in their 
assays.  It  is  important  to  establish  the  receptor  tar-
geting  specificity  by  several  different  ways:  1)  the 
compound  can  bind  and  be  internalized  by  recep-
tor-positive  cell  lines,  2)  the  cell  binding  and  inter-
nalization of the compounds can be blocked with ex-
cessive  amount  of  a  free  ligand  either  pre-  or 
co-incubated  with  the  cells,  and  3)  no  measureable 
cellular binding and internalization occurs with either Theranostics 2011, 1 
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receptor-negative  cell  lines  or  cells  from  which  the 
receptor has been cleaved [28, 45]. 
3. In vivo studies: The compounds can be studied 
for their tumor uptake, bio-distribution, and related 
kinetics using noninvasive optical imaging system. In 
vivo  specificity  can  similarly  be  evaluated  by:  1) 
comparing uptake of the compound in a known re-
ceptor-positive tumor with its uptake in several re-
ceptor-negative tissues; 2) examining the competitive 
blockade  of  the  compound’s  localization  in  tumor 
upon pre-or co-injection of the animal with excessive 
amount of a free ligand [28, 45].  
The  primary  goal  of  integrin-targeting  optical 
agents  is  for  targeted  delivery  of  optical  imaging 
agents to improve the image contrast and accuracy. 
Nonspecific binding is usually hard to avoid, leading 
to  obscure  imaging  results  in vivo.  The  in vivo  per-
formance of an optical agent might also be devalued 
by  its  decomposition,  metabolism,  distribution,  and 
excretion  in  the  complex  in vivo  environments.  Fre-
quently, the in vitro and in vivo results may be am-
biguous and contradictable, which have highlighted 
the continuing efforts to the discovery of some new 
optimal  optical  agents  for  tumor  optical  imaging. 
Some  more  complex  activatable  optical  imaging 
agents  have  been  reported.  New  integrin-targeted 
optical  imaging  agents  have  also  been  adapted  for 
multimodal imaging and new optical imaging meth-
ods. All these have represented the new generation of 
targeted optical agents.  
3. NIR Fluorescent RGD Peptides  
Among the known 24 integrin subtypes, integrin 
αvβ3 has been widely investigated for tumor imaging 
and therapy due to its important roles in angiogene-
sis, growth, and metastasis of some tumors. Especial-
ly,  integrin  αvβ3  has  been  an  attractive  marker  for 
diagnostic imaging of tumor angiogenesis due to its 
high expression on activated and proliferating endo-
thelial cells during tumor angiogenesis and metastasis 
in contrast to resting endothelial cells and most nor-
mal  organs.  Integrin  αvβ3  binds  some  extracellular 
matrix proteins such as vitronectin via Arg-Gly-Asp 
(RGD)  sequence,  so  diverse  RGD  peptide  ligands 
have been developed to target integrin αvβ3 and an-
giogenic vessels. Among them, a class of cyclic RGD 
penta-peptide  analogs  including  c(RGDfV)  and 
c(RGDfK) is outstanding for its high receptor binding 
affinity  and  specificity.  Various  types  of  imaging 
probes for diagnostic imaging have been discovered 
based on such a type of cyclic RGD peptide template. 
For  example,  18F-galacto-RGD  i.e.  18F-labeling 
RGD-containing glycopeptide has been studied with 
melanoma,  sarcoma,  and  breast  cancer  patients  in 
clinical  trials  [36-37].  Therefore,  many  integrin 
αvβ3-targeted optical imaging agents have been built 
on the cyclic RGD template similarly.  
Two  Cy5.5-labeled  cyclic  RGD  analogs  i.e. 
Cy5.5-(RGDfK) and Cy5.5-(RGDyK) (Fig. 3) were first 
reported for in vivo optical imaging of integrin αvβ3 
positive tumors in mouse models and showed high 
contrast images [46-47]. Gurfinkel et al. reported dy-
namic fluorescence imaging of a subcutaneous human 
Kaposi's  sarcoma  tumor  (KS1767)  model  by  the  in-
travenous injection of Cy5.5-c(RGDfK). The dye con-
jugate  had  specific  tumor  uptake  which  can  be 
blocked by c(RGDfK) [48]. As reported by Chen et al. 
[46], 1.5 nmol monomeric Cy5.5-RGD was injected via 
the tail vein in an orthotopic brain tumor model and 
detected by a three-dimensional optical imaging sys-
tem (IVIS 200) 0–24 hours. The highest tumor uptake 
and tumor to normal brain tissue ratio were observed 
two  hours  post-injection  (2.64±0.20).  The  tumor  up-
take  of  Cy5.5-RGD  was  effectively  blocked  by 
c(RGDyK). Fluorescence microscopy further demon-
strated specific Cy5.5-RGD binding to  both U87MG 
tumor vessels and tumor cells without normal tissue 
binding  compared  with  the  nonspecific  binding  of 
Cy5.5.  
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Figure 3. The structures of both Cy5.5-c(RGDfK) (X: H) 
and Cy5.5-c(RGDyK) (X: OH). 
 
NIR  fluorescent  Cy5.5-E{E[c(RGDyK)]2}2  Strong 
and  specific  receptor  binding  of  a  probe  to  the  cell 
surface receptor is important for successful receptor 
targeting and tumor imaging.  The monomeric RGD 
analog showed promising results both in vitro and in 
vivo  but  its  moderate  integrin  binding  affinity  may 
weaken  tumor  uptake  and  related  in  vivo  perfor-
mance. Dimerization or multimerization of the cyclic 
RGD peptide provided a viable approach to improve 
the binding affinity and in vivo imaging [35, 42, 45]. 
For  example,  various  dimeric  and  tetrameric  RGD Theranostics 2011, 1 
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analogues  including  E-[c(RGDfK)]2, 
E-[G-G-G-c(RGDfK)]2,  and  E-{G-[c(RGDfK)]2}2,  were 
prepared and labeled with various radionuclides such 
as  18F,  64Cu,  68Ga,  and  99mTc.  All  the  peptides  had 
stronger binding than the monomeric counterpart in 
integrin αvβ3-positive U87MG xenograft models. The 
improvements  might  be  ascribed  to  the  increased 
“local concentration” of the RGD peptide in the vicin-
ity of receptors for synergistic interactions with the 
receptors. These peptide probes may serve as valuable 
tools for nuclear imaging of tumor angiogenesis with 
great  potentials  in  the  clinic.  One  18F-labeled  RGD 
dimer, i.e.  18F-FPPRGD2, has been approved for ex-
ploratory investigative new drug application by FDA. 
All  these  results  spurred  further  studies  on  these 
multivalent RGD and their interactions with integrin 
αvβ3 by optical imaging in the tumor-bearing mouse 
models. 
Cheng  et  al.  [45]  evaluate 
three  novel  NIRF  probes  i.e. 
monomeric  Cy5.5-c(RGDyK), 
dimeric  Cy5.5-E[c(RGDyK)]2, 
and  tetrameric 
Cy5.5-E{E[c(RGDyK)]2}2 (Fig. 4) 
in a subcutaneous U87MG glio-
blastoma xenograft model. The 
binding  affinities  of 
Cy5.5-conjugated  RGD  mono-
mer,  dimer,  and  tetramer  for 
integrin  αvβ3  expressed  on 
U87MG  cell  surface  were  42.9±1.2,  27.5±1.2,  and 
12.1±1.3 nM, respectively. The subcutaneous U87MG 
tumor was clearly visualized with the three fluores-
cent  probes.  All  the  three  compounds  had  integrin 
specific uptake both in vitro and in vivo. The tetramer 
displayed highest tumor uptake and tumor-to-normal 
tissue  ratio  from  0.5  to  4  h  post-injection.  Tu-
mor-to-normal tissue ratios at 4 h postinjection were 
found to be 3.18 ± 0.16 (monomer), 2.98 ± 0.05 (dimer), 
and 3.63 ± 0.09 (tetramer), respectively. The tetramer-
ization  of  RGD  peptide  resulted  in  moderate  im-
provement  of  imaging  characteristics,  compared  to 
that of the monomer and dimeric counterparts. These 
results  suggest  that  Cy5.5-labeled  monomeric,  di-
meric, and tetrameric RGD peptides all have potential 
for  imaging  of  integrin  expression.  Such  probes 
should be also valuable for further studying the re-
lated integrin αvβ3-mediated signaling transductions.  
 
 
 
Figure 4. The structures of three 
Cy5.5-  RGD  conjugates,  i.e. 
monomer Cy5.5-c(RGDyK), dimer 
Cy5.5-E[c(RGDyK)]2, and tetramer 
Cy5.5-E{E[c(RGDyK)]2}2. 
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IRDye800-E[PEG4-c(RGDfK)]2 Recently, Liu et al. 
further  studied  optical  imaging  of  tumor  integrin 
αvβ3 expression by using a near-infrared fluorescent 
IRDye®800CW-labeled cyclic RGD dimer with a tet-
ra(ethylene  glycol)  (PEG4)  linker  i.e., 
E[PEG4-c(RGDfK)]2,  PEG4=15-amino-4,7,10,13 
tetraoxapentadecanoic acid) in a U87MG tumor mod-
el. In vivo NIRF imaging showed higher tumor accu-
mulation  and  tumor  to  background  contrast  of 
IRDye800-E[PEG4-c(RGDfK)]2  over 
IRDye800-E[c(RGDfK)]2 without the PEG4 linker. The 
tumor  integrin  αvβ3  specificity  of 
IRDye800-E[PEG4-c(RGDfK)]2  was  confirmed  by  in-
hibition  of  tumor  uptake  using  an  excess  dose  of 
c(RGDfK) [42].  
Cy5-labeled RAFT-c(-RGDfK-)4  A  new NIR fluo-
rescent  Cy5-labeled  tetrameric  RGD  peptide  conju-
gate based on a cyclic decapeptide as regioselectively 
addressable, functionalized template (RAFT) was re-
ported [49,50]. Four copies of the c(RGDfK) peptide 
were linked to the upper face of the RAFT platform 
while  Cy5  was  attached  to  its  bottom  face  to  give 
Cy5-RAFT-c(RGDfK)4  (Fig.  5)  for  optical  imaging. 
This tetramer differs from the previous tetramer by 
the topological separation of two independent func-
tional domains i.e. integrin αvβ3 targeting domain and 
optical  imaging  domain.  Cy5-RAFT-c(RGDfK)4  effi-
ciently accumulated into tumors in nude mice. This 
compound  was  also  evaluated  for  its  potential  in 
noninvasive detection of deep ovarian metastases on 
subcutaneous  tumors  and  intraperitoneal  human 
ovarian adenocarcinoma IGROV1 cells with low lev-
els  of  integrin  αvβ3  expressing  metastases  in  nude 
mice. Noninvasive optical imaging showed that the 
compound  exhibited  stronger  staining  in  vitro,  en-
hanced tumor-to-background ratio for subcutaneous 
tumors,  and  allowed  early  detection  of  1-  to  5-mm 
large  intra-abdominal  nodules.  Histological  study 
revealed that the compound accumulated into tumor 
neovasculature but also into tumor cells. The results 
demonstrate that Cy5-RAFT-c(RGDfK)4 is an efficient 
optical probe for early, noninvasive tumor detection. 
This compound was also tested with the human em-
bryonic  kidney  cells  HEK293(β3) (high  levels  of  in-
tegrin αvβ3) or HEK293(β1) (integrin αvβ3-negative 
but expressing αV and β1) engrafted subcutaneously 
in mice. Compared to its monomeric cyclic RGD ana-
logue, Cy5-RAFT-c(RGDfK)4 had higher uptake and 
longer retention with markedly enhanced contrast in 
HEK293(β3)  than  in  the  HEK293(β1)  tumors.  Intra-
venous injection of Cy5-RAFT-c(RGDfK)4 in this pair 
of  HEK293(β3) and  HEK293(β1)  tumors  provided  a 
tumor/skin ratio above 15. Blocking studies further 
demonstrated  the  targeting  specificity  of  the  com-
pound. 
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Figure 5. Schematic structure of Cy5-RAFT-c(RGDfK)4. 
Integrin αvβ3 targeted dual-modality imaging agents 
The  challenges  of  cancer  diagnosis,  detection,  and 
even  therapy  have  highlighted  the  combination  of 
different imaging modalities in clinic to harness the 
different  features  of  each  modality.  As  described 
above, the strength and weakness of optical imaging 
include cost effectiveness, facile use, safe application, 
high  sensitivity,  low  tissue  penetration  depth,  and 
limited  applications  in  clinic.  There  are  some  fused 
X-ray/CT-fluorescence  imaging  systems.  Especially, 
nuclear imaging including both PET and SPECT has 
found  wide applications in biomedicines. There are 
tremendous  advances  in  multimodality  imaging  of 
tumor  integrin  αvβ3  expression  by  magnetic  reso-
nance imaging (MRI), ultrasound, near-infrared (NIR) 
fluorescence,  single  photon  emission  computed  to-
mography (SPECT), and positron emission tomogra-
phy  (PET)  [51-53].  Several  groups  have  been  inter-
ested in some novel dual labeling molecules for both 
optical imaging and nuclear imaging. It may provide Theranostics 2011, 1 
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a way to overcome the shortcomings and limitations 
of nuclear imaging in spatial resolution and radiation 
safety. Especially, it would be very significant to dis-
cover novel integrin-targeted dual imaging agents for 
integrating both highly sensitive and complementary 
nuclear  and  optical  techniques.  Such  simultaneous 
dual imaging by the same molecule may reveal more 
accurate, comprehensive information of the  integrin 
expression  and  functions  at  different  anatomical, 
functional and molecular levels in oncology, facilitat-
ing  their  structural  modification,  evaluation,  and 
mechanism  studies  for  successful  translation  into 
clinical applications. 
Li et al. reported the synthesis and evaluation of 
a dual-labeled RGD (Arg-Gly-Asp) peptide conjugate 
111In-DTPA-Lys(IRDye800)-c(KRGDf)  composed  of 
both the  111In chelator diethylenetriaminepentaacetic 
acid (DTPA) and the near-infrared (NIR) fluorescent 
dye IRDye800 (excitation/emission, 765/792 nm) for 
dual optical and nuclear imaging in human melano-
ma xenografts [51]. Mice of tumors injected with the 
dual-labeled  probe  were  imaged  by  both  gamma 
scintigraphy  and  NIR  fluorescence  optical  camera. 
DTPA-Lys(IRDye800)-c(KRGDf),  DTPA-Lys-c 
(KRGDf)  and  c(KRGDf)  inhibited  the  adhesion  of 
melanoma  M21  cells  to  vitronectin-coated  surface 
with similar biological activity. The dual-labeled im-
aging  probe  111In-DTPA-Lys(IRDye800)-c(KRGDf) 
(Fig. 6) was found to specifically bind to integrin αvβ3 
in  melanoma  tumor  cells.  Both 
111In-DTPA-Lys(IRDye800)-c(KRGDf)  and 
111In-DTPA-Lys-c(KRGDf)  had  significantly  higher 
uptakes  in  integrin  αvβ3-positive  M21  melanoma 
than  in  integrin  αvβ3-negative  M21-L  melanoma  at 
4–48 h after their injection. Side-by-side comparison of 
images  obtained  using  111In-DTPA-Lys 
(IRDye800)-c(KRGDf) revealed that both optical im-
aging and gamma scintigraphy enabled noninvasive 
detection of the probe bound to integrin αvβ3-positive 
tumors  in  living  mice.  Optical  images  provide  im-
proved resolution and sensitive detection of the su-
perficial lesions while gamma images provide sensi-
tive detection of deeper structures.  
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Figure 6. The structures of 
111In-DTPA-Lys(IRDye800)-c(RGDfK) and DOTA-cypate-cyclo(RGDfK) (LS308). Theranostics 2011, 1 
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Edwards  et  al.  reported  another  integrin 
αvβ3-targeted  dual  imaging  probe  LS308  bearing  a 
cyclic  RGDfK  peptide,  a  tetraazamacrocycle 
1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraaceti
c acid (DOTA) and a near-infrared (NIR) fluorescent 
dye cypate [54]. LS308 had a high affinity for integrin 
αvβ3  and  internalized  preferentially  via  integrin 
αvβ3-mediated  endocytosis  in  firefly  luciferase 
transfected 4T1cells. It also selectively accumulated in 
integrin  αvβ3-positve  tumors  in  a  receptor-specific 
manner.  The  tumor  was  visualized  by  biolumines-
cence (fluc reporter gene), NIR fluorescence (cypate), 
and SPECT (111In).  
As described below, some integrin-targeted dual 
labeling nanoparticles for both optical and PET have 
been reported.  Such a kind of integrin-targeted du-
al-labeling  imaging  agents  can  fully  take  the  ad-
vantages of nanotechnology to discover novel multi-
functional  imaging  agents  which  are  valuable  for 
better understanding of the disease and related bio-
logical  events  for  improving  disease  diagnosis  and 
detection.  
Integrin-targeted activatable optical probes Activat-
able  optical  probes  refer  to  some  fluorescently 
quenched  molecules  which  can  undergo  enzymatic 
conversion to become fluorescently active for optical 
imaging  in  a  certain  environment  [55-57].  They  are 
usually obtained by attaching one fluorophore with 
another fluorophore or a quencher via a certain linker 
which can be cleaved by some enzymes. Many pep-
tide-based activatable probes can serve as important 
tools for studying the localization, visualization, and 
determination of the intrinsic enzyme activities such 
as MMPs and caspases involved in cancer, inflamma-
tion,  and  vascular  disease  by  optical  imaging.  The 
strategy has also become attractive for its potential in 
improving the image contrast with better signal-noise 
ratio. Tung et al. reported the first MMP-activatable 
probe  based  on  a  poly-lysine  polymer  conjugated 
with a MMP substrate Gly-Pro-Leu-Gly-Val-Arg and 
Cy5.5, allowing for self-quenching of Cy5.5 by fluo-
rescence resonance energy transfer (FRET) [55]. Lee et 
al.  reported  a  dark-quenched  MMP-13  activatable 
peptide  probe,  Cy5.5-Gly-Pro-Leu-Gly-Met-Arg-Gly- 
Leu-Gly-Lys(BHQ-3), for optical imaging of MMP-13 
in a rat osteoarthritis model [58]. Tsien et al. reported 
in vivo  visualization  of  MMP  activities  by  MRI  and 
fluorescence of dendrimeric nanoparticles coated with 
activatable cell penetrating peptides (ACPPs), labeled 
with  Cy5,  gadolinium,  or  both.  Such  nanoparticles 
had 4- to 15-fold higher uptake in tumors than un-
conjugated  ACPPs  [59].  There  are  some  reports  on 
integration of the activatable optical probes and in-
tegrin targeting into in vivo tumor optical imaging. 
Razkin et al. reported several integrin-targeted 
NIR  fluorescent  activatable  probes  for  tu-
mor-targeting imaging in live mice [60]. These include 
RAFT-(cRGD)4  Cy5-S  S-Cy5  (1),  RAFT-(cRGD)4 
Cy5-S  S-QSY21  (2),  and  RAFT-(cRGD)4  QSY21-S 
S-Cy5 (3) built on a RAFT as mentioned above (Fig. 7). 
Such  molecules  have  topological  separation  of  two 
independent  functional  domains  i.e.  integrin  αvβ3 
targeting domain and imaging domain. The imaging 
domain consists of two Cy-5 dyes or Cy5 and a dia-
rylrhodamine  derivative  quencher  (QSY21)  linked 
with a disulfide bond for fluorescence quenching. The 
disulfide bonds are cleaved for fluorescence activation 
after the integrin-mediated cellular internalization of 
the three probes because disulfide bridges are known 
to be reduced enzymatically by thioredoxines in the 
cytosol. That was first demonstrated in vitro by using 
2-mercaptoethanol  (2-MCE)  and  the  results  showed 
100 % recovery upon the S-S bond cleavage. Confocal 
microscopy  confirmed  the  cellular  uptake  of 
RAFT-(cRGD)4  Cy5-S  S-Cy5  by  live  HEK293  cells 
overexpressing integrin αvβ3 after 1.5 h incubation at 
37 °C. It showed weaker staining of the cell membrane 
than the control compound RAFT(cRGD)4 Cy5. The 
intracellular  signal  from  the  quenched  probe  ap-
peared  with  a  higher  contrast,  suggesting 
site-selective  fluorescence  activation.  The 
co-localization of RAFT-(cRGD)4 Cy5-S S-Cy5 and a 
lysosome-labeling dye (LysoTracker Green) suggests 
lysosome as the possible cleavage location for the di-
sulfide bond. No fluorescence increase was observed 
upon  incubation  at  37  °C  of  1  M  of  the  activatable 
Cy5-S S-Q, in plasma or whole blood, for at least 120 
min, showing its relative stability in blood. The two 
compounds i.e. 1 and 2 in PBS 10 mM (pH 7.4, with 10 
% DMSO, 10 % EtOH) were injected intravenously at 
10  nmol  Cy5  per  mouse  into  mice  of  subcutaneous 
integrin αvβ3-positive human ovarian cancer cell line 
IGROV1 tumor for whole body fluorescence imaging. 
The  Cy5  fluorescence  recovery  of  the  activatable 
probes was found slow and the image contrast was 
greatly augmented 5 h post-injection in comparison to 
the  previously  described  RAFT-(cRGD)4  Cy5  mole-
cule. The unquenched probe RAFT-(cRGD)4 Cy5 ac-
cumulated in the tumor a few minutes post-injection, 
but the presence of unbound circulating molecules in 
normal  tissues  greatly  reduced  the  tu-
mor/background ratio (contrast). 
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Figure 7. The structures of RAFT-(cRGD)4 Cy5-S S-Cy5 (1), RAFT-(cRGD)4 Cy5-S S-QSY21 (2), and RAFT-(cRGD)4 
QSY21-S S-Cy5 (3). 
 
 
 
Apoptosis  is  a  programmed  cell  death  process 
aberrantly involved in the pathogenesis of many dis-
eases. Most of the anticancer drugs work by initiating 
apoptosis;  thus,  the  imaging  and  detection  of  the 
apoptosis progression could guide the evaluation of 
cancer chemotherapy. Caspases make up a family of 
cysteine proteases and are crucial mediators of apop-
tosis. To detect apoptosis-associated caspase activity 
in  vivo,  caspase-activatable  NIR  fluorescent  probe 
based on a fluorophore pair of Alexa Fluor 647 and 
QSY  21  as  well  as  a  cell-permeable  peptide  motif 
Lys-Lys-Lys-Arg-Lys-Val, and a caspase peptide sub-
strate Asp-Glu-Val-Asp has been reported for imag-
ing of caspase activity in apoptotic cells in vitro. Lee et 
al.  reported  a  complex  multifunctional  molecule 
LS498 containing 5 components including DOTA, two 
quenched fluorophores, capase-3 substrate DEVDAP 
and  integrin-targeting  RGD  to  combine  the  two 
strategies  i.e.  caspase-3  activation  and  integ-
rin-targeting for tumor optical and nuclear imaging 
(Fig.  8) [52]. The fluorescence was  quenched in the 
native form and was readily cleaved by caspase-3 to Theranostics 2011, 1 
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become fluorescent. In mice, the initial fluorescence of 
LS498  was  ten-fold  less  than  control.  A 
time-dependent five-fold NIR fluorescence enhance-
ment was observed using radiolabeled 64Cu-LS498 in a 
controlled  and  localized  in  vivo  model  of caspase-3 
activation,  but  radioactivity  remained  identical  in 
both caspase-3 positive and negative controls.  
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Figure 8. The structure of LS498. 
 
Compared  with  conventional  integrin-targeted 
agents, such integrin-targeted activatable probes rep-
resent  a  higher  level  of  structural  sophistication.  In 
addition  to  small  molecules  described  above,  nano-
particles including polymer conjugates and inorganic 
nanoparticles have also been used for construction of 
activatable probes. All these have further expanded 
the scope and applications of  integrin-targeted acti-
vatable optical probes. 
New integrin targeting peptides for optical imaging 
Strong  evidences  from  nuclear  and  optical  imaging 
showed the applications of specific integrin αvβ3 and 
αvβ5 antagonists such as cyclic RGD peptides in tar-
geted  delivery  of  imaging  agents  for  in vivo  tumor 
imaging  targeting.  Inhibitors  of  integrin  αvβ3  and 
αvβ5  have  entered  clinical  trials  as  antiangiogenic 
agents for cancer treatment but generally have been 
unsuccessful. Recently, it is reported that nanomolar 
concentrations  of  RGD-mimetic  integrin  αvβ3  and 
αvβ5 inhibitors can promote VEGF-mediated tumor 
angiogenesis and tumor growth in mice which may 
seriously  compromise  the  anticancer  activity  of 
RGD-mimetic integrin αvβ3 and αvβ5 inhibitors. That 
finding  might  explain  the  ineffectiveness  of  such 
RGD-mimetic integrin αvβ3 and αvβ5 inhibitors for 
cancer therapy for the majority of human cancers in 
clinic.  It  has  also  rationalized  discovery  and  devel-
opment of new integrin ligands which are structurally 
and functionally different from the conventional cy-
clic RGD-based integrin αvβ3 and αvβ5 antagonists as 
oncologic  drugs.  Many  new  integrin  ligands  have 
been reported and show promising results for optical 
imaging.  
Carlson  et  al.  demonstrated  the  advantages  of 
low-affinity,  multivalent  interactions  for  selective 
tumor  cell  targeting  over  traditional,  abiotic, 
high-affinity targeting methods [61]. They used a bi-
functional  small-molecule  ligand  composed  of  two 
motifs: (1) an RGD peptidomimetic with tight binding 
to integrin αvβ3 (Kd ≈ 10 nM) and (2)  the galacto-
syl-α(1–3)galactose  (α-Gal  epitope)  recognized  by 
human  anti-α-galactosyl  antibodies  (anti-Gal).  The 
bifunctional  conjugate  decorates  a  cell  possessing  a 
high  level  of  integrin  αvβ3  to  generate  multivalent 
displays  of  α-Gal  epitopes  at  cell  surface  which  is 
important  for  recruiting  anti-Gal  and  thereby  trig-
gering  complement-mediated  lysis.  These  results 
highlight the advantages of exploiting the type of the 
multivalent recognition processes used by physiolog-
ical systems to discriminate between cells. The results 
have  implications  for  the  treatment  of  cancer  and 
other diseases characterized by the presence of dele-
terious cells.  
Ye  et al.  synthesized  and  evaluated  a  series  of 
multimeric  RGD  compounds  based  on  the  simple 
RGD  unit  and  a  dicarboxylic  acid-containing 
near-infrared (NIR) fluorescent dye (cypate) scaffold 
for tumor targeted optical imaging [40]. Some novel 
NIR fluorescent RGD compounds were thus obtained 
efficiently,  including  one  RGD  monomer  (cy-Theranostics 2011, 1 
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pate-(RGD)2-NH2),  two  RGD  dimers  (cy-
pate-(RGD)2-NH2  and  cypate-(RGD-NH2)2),  one  tri-
mer  (cypate-(RGD)3-NH2),  two  tetramers  (cy-
pate-(RGD)4-NH2  and  cypate-[(RGD)2-NH2]2),  one 
hexamer  (cypate-[(RGD)3-NH2]2),  and  one  octamer 
(cypate-[(RGD)4-NH2]2) (Fig. 9). The binding affinity 
of the multimeric RGD compounds for integrin αvβ3 
showed a remarkable increase relative to the mono-
mer cypate-RGD-NH2. Generally, the divalent linear 
arrays  of  the  multimeric  RGD  units  bound  integrin 
αvβ3 with slightly higher affinity than their monova-
lent analogues. These results suggest that the receptor 
binding  affinity  was  not  only  dependent  on  the 
number  of  RGD  moieties  but  also  on  the  spatial 
alignments of the pendant peptides. Internalization of 
the compounds by integrin αvβ3-positive tumor cells 
(A549)  was  monitored  by  NIR  fluorescence  micros-
copy.  The  data  showed  that  endocytosis  of  the  oc-
tameric RGD derivative was significantly higher by 
comparison to other compounds in this study. In vivo 
noninvasive optical imaging and biodistribution data 
showed that the compounds were retained in A549 
tumor tissue. Some integrin-targeted ligands with low 
affinity showed good tumor targeting and imaging in 
vivo, so should not be ignored. 
von Wallbrunn  et  al.  [63]  synthesized  a  disul-
fide-based  cyclic  RGD  labeled  with  a  cyanine  dye 
(Cy5.5) for optical imaging of integrin αvβ3 expression 
in  tumor  xenografts  using  both  two-dimensional 
planar (FRI) and three-dimensional tomographic op-
tical  imaging  methods  (FMT)  (Fig.  10,  upper).  The 
peptide-dye conjugate showed a significant binding 
with  integrin  αvβ3-positive  M21  and  HT-1080  cells 
while  it  had  little  to  no  fluorescence  staining  with 
integrin αvβ3-negative MCF-7 cells. Tumor xenografts 
were clearly visualized by FRI and FMT up to 24 h 
post injection. FMT allowed quantification of the flu-
orochrome distribution in deeper tissue sections. The 
average  fluorochrome  concentrations  at  60 min 
post-injection  of  the  probe  were  found  at 
417.61 ± 105.82 nM  Cy5.5  (M21),  353.68 ± 54.02 nM 
Cy5.5  (HT-1080)  and  262.83 ± 155.36 nM  Cy5.5 
(MCF-7) in the target tissue. Competition with the free 
RGD  peptide  resulted  in  a  reduction  in  the  fluoro-
chrome  concentration  in  M21  tumour  tissue 
(294.35 ± 84.27 nM).  
Most of the conventional RGD peptides only de-
livered the cargo to the blood vessels. Ruoslahti group 
reported  a  tumor-homing  peptide  iRGD 
(CRGDKGPDC) discovered by phage display for tis-
sue-penetrating delivery [64]. Intravenous injection of 
iRGD conjugates bound to tumor vessels and spread 
into the extravascular tumor parenchyma to improve 
the sensitivity of tumor-imaging agents and enhance 
the  activity  of  an  antitumor  drug.  The  tis-
sue-penetrating  delivery  involves  a  three-step  pro-
cess: 1) the binding of RGD motif to αv integrins on 
tumor endothelium; 2) a proteolytic cleavage of the 
iRGD for binding with neuropilin-1; 3) neuropilin-1 
mediated penetration into tissue and cells. Recently, 
we synthesized a near-infrared fluorescent analog i.e. 
IRDye800-iRGD conjugate which showed significant 
tumor localizationin optical imaging of MDA-MB-435 
tumor xenograft-bearing nude mice (Fig. 10).  
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Figure 10. The structures of two disulfide-based cyclic RGD conjugates. 
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Figure 11. The structure of fluorescently labeled nonpeptidic integrin-targeting compound.  
 
In addition to diverse conventional RGD peptide 
analogs,  many  nonpeptidic  compounds  or  pep-
tidomimetics have also received wide attentions for 
integrin targeting. For example, Heroux et al. reported 
a synthetic integrin αvβ3-targeted fluorescent probe 
which had at least 20 times stronger binding affinity 
for integrin αvβ3than the commercially available cy-
clic  peptide  c[RGDfv]  (Fig.  11).  The  compound 
showed good tumor targeting in vivo as demonstrated 
by fluorescence imaging. It can identify the site and 
extent  of  integrin  αvβ3  expression  correlated  with 
adventitial thickness in Watanabe Rabbits, serving as 
a  new  imaging  biomarker  for  early  atherosclerotic 
disease [65]. 
Optical  imaging  of  α4β1  integrin  Increasing  evi-
dences suggest that integrin α4β1 plays a pivotal role Theranostics 2011, 1 
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in  autoimmune  diseases  and  cancer  development. 
Due  to  the  lack  of  high-affinity  targeting  ligands, 
molecular imaging of integrin α4β1 is much less ex-
plored than that of integrin αvβ3 and αvβ5 integrins. 
The Lam group identified a peptidomimetic, LLP2A, 
that  preferentially  binds  to  activated  integrin  α4β1 
using  the  one  bead–one  compound  combinatorial 
library method [66]. They further labeled it with Cy5.5 
to form LLP2A-Cy5.5 (Fig. 12) for in vivo optical im-
aging of human lymphoma xenograft. LLP2A-Cy5.5 
retained the binding activity and specificity to integ-
rin α4β1 as shown by cell binding assays using integ-
rin  α4β1-positive  Molt-4  T-leukemia  cells.  The  sub-
cutaneous Molt-4 tumor was clearly visualized from 1 
to 24 h after tail vein injection of the conjugate. Tumor 
uptake  of  LLP2A-Cy5.5  conjugate  was  blocked  by 
excess unlabeled LLP2A. The accumulation of LLP2A 
in tumors was further confirmed by both direct im-
aging  and  confocal  microscopic  examination  of  ex-
cised tumors and organs with very little or no uptake 
in  normal  organs  except  for  lymph  nodes.  Kidney 
uptake was high when the whole organ was scanned 
but it was negative when examined microscopically, 
suggesting  that  LLP2A  bound  to  the  renal  tubules 
loosely.  This  study  showed  that  LLP2A-Cy5.5  can 
serve as an optical imaging probe for noninvasively 
monitoring of activated integrin α4β1 in vivo.  
Optical imaging of integrin α3 Through screening 
random one-bead one-compound (OBOC) cyclic pep-
tide libraries, Aina et al. previously reported a cyclic 
peptide motif, cDGXGXXc can bind preferentially to 
ovarian cancer with high specificity against α3 integ-
rin  [67].  A  cXGXGXXc-focused  library  was  synthe-
sized and screened against U87MG human glioblas-
toma cells as integrin α3β1 is the major integrin sub-
type expressed in glioma cells. A new cyclic peptide 
cdGLGBNc (named LXY1, B:  L-hydroxyproline) was 
found to be an excellent ligand against U87MG cells. 
Further studies showed LXY1 can bind with the in-
tegrin α3 of U87MG cells with moderately high affin-
ity (Kd = 0.5 ± 0.1 μM) and high specificity. The α3 
targeting of LXY1 was demonstrated by optical im-
aging in tumor-bearing mouse models [68]. A com-
plex from biotinylated LXY1 and streptavidin-Cy5.5 
(SA-Cy5.5),  i.e.  LXY1-biotin/SA-Cy5.5  could  target 
both subcutaneous and orthotopic U87MG xenograft 
implants in nude mice. The tumor uptake was inhib-
ited by intravenous injection of anti-α3 integrin anti-
body  or  excess  unlabeled  LXY1.  LXY1-Cy5.5  conju-
gate (2,279 Da) (Fig. 13) was found to have a faster 
accumulation in the U87MG tumor and shorter reten-
tion  time  compared  with  the  tetravalent 
LXY1-biotin/SA-Cy5.5  complex  (approximately  64 
kDa). The studies demonstrated the potential of LXY1 
for integrin α3-targeted molecular imaging and ther-
apy of human glioblastoma.  
Based on the established structure-activity rela-
tionship (SAR) study, two highly focused cyclic pep-
tide libraries were further designed, synthesized, and 
screened  against  MDA-MB-231  breast  cancer  cells 
under  stringent  conditions.  A  novel  cyclic  peptide 
(LXY3) with a high binding affinity (IC50 = 57 nM) was 
identified.  Moreover,  the  targeting  efficiency  and 
specificity of LXY3 to the breast adenocarcinoma tu-
mors in mouse xenografts were further confirmed by 
in vivo and ex vivo optical imaging [69]. 
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Cypate-GRDSPK targeting integrin β3 By evaluat-
ing a small library of RGD peptides for optical imag-
ing of integrin αvβ3-positive tumor cell line (A549), 
Achilefu’s  group  discovered  a  linear  hexapeptide 
GRDSPK conjugate with cypate (cypate-GRD) targets 
integrin  αvβ3-positive  tumors  (Fig.  14)  [41].  MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide] assay with A549 cells 
showed that Cypate-GRD was not cytotoxic up to 100 
μM in cell culture. Its internalization into A549 cells 
was  blocked  by  co-incubation  with  cyclo(RGDfV). 
Cypate-GRD selectively accumulated in tumors rela-
tive to surrounding normal tissues in vivo which was 
also blocked by cyclo[RGDfV], suggesting that both 
compounds might target the same active site of the 
receptor. Interestingly, neither a Cypate-labeled linear Theranostics 2011, 1 
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RGD peptide nor an 111In-labeled DOTA-GRD conju-
gate was selectively retained in the tumor. These re-
sults  clearly  demonstrate  the  synergistic  effects  of 
Cypate and GRD peptide for molecular recognition of 
integrin expression and suggest the potential of using 
carbocyanines  as  optical  scaffolds  for  constructing 
novel  -receptor-targeting  molecules.  Further  studies 
with functional blocking antibodies and β3 knockout 
cells revealed that β3 integrin mediates the internali-
zation of the cypate-GRD peptide. Molecular model-
ing studies supported preferential interaction of this 
probe with the β3 subunit of integrins relative to the αv 
subunit [62]. 
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Figure 14. The structure of cypate-GRDSPK (cypate-GRD). 
 
Integrin-targeted fluorescent nanoparticles for optical 
imaging  and  therapy  The  convergence  of  molecular 
imaging,  nanotechnologies,  and  targeted  delivery 
have  produced  profound  impacts  on  biomedicines. 
Nanoparticles  have  become  increasingly  important 
for cancer early detection, diagnosis, and therapy be-
cause many functionalities can be incorporated to the 
surface and interior of the particle. Various types of 
nanoparticles such as quantum dots (QDs), magnetic 
iron  oxide  nanoparticles,  polymeric  nanoparticles, 
carbon nanotubes, and gold nanoparticles have been 
discovered  andhave  advantages  for  cancer  imaging 
and therapy. The nano-sized materials show unique 
optical, magnetic, and other physicochemical proper-
ties.  Importantly,  many  complex  fluorescent  nano-
particles including QDs and some Cy5 labeled nano-
particles are attractive for optical imaging. Generally, 
nanoparticles  suffer  from  some  drawbacks  in  non-
specific accumulation, circulation time, and biocom-
patibility. In addition, their safety profiles of metabo-
lism and toxicity have not been established and are 
still a big concern for a long-term in vivo application. 
These drawbacks might be overcome by appropriate 
modifications  of  the  nanoparticle  composition  and 
structure  for  targeted  delivery  to  achieve,  desirable 
pharmacokinetics  and  pharmacodynamics  with  im-
proved  stability,  controlled  in  vivo  circulation,  tis-
sue-selective accumulation, and toxicity in the body. 
Some  new  innovative  multifunctional  nanoparticle 
agents  with  improved  targeting  efficacy  and  bio-
compatibility for multimodality imaging and targeted 
therapy  have  been  discovered  by  integrating  integ-
rin-targeting, optical imaging and even complemen-
tary multimodality imaging motifs into nanoparticle 
constructs.  Described  below are some typical  integ-
rin-targeted  nanoparticle-based  optical  imaging 
agents. 
RGD-bearing quantum dots for optical imaging The 
common  QD  fluorophores  are  made  of  cadmium 
selenide (CdSe) cores overcoated with a layer of ZnS. 
In  comparison  with  organic  dyes  and  fluorescent 
proteins,  QDs  have  unique  optical  and  electronic 
properties  such  as  size-tunable  light  emission,  im-
proved signal brightness, photobleaching resistance. 
QDs are similar to proteins in their dimensions and 
can be used as fluorescent labels, much like GFP. QDs 
have  been  emerging  as  a  new  class  of  fluorescent 
probes  for  biomedical  imaging.  Bioconjugated  QDs 
have  raised  new  possibilities  for  ultrasensitive  and 
multiplexed  imaging  of  molecular  targets  in  living 
cells and animal models [17, 70-72]. A new structural 
design involves encapsulating luminescent QDs with 
amphiphilic block copolymers, and linking the poly-
mer  coating  to  tumor-targeting  ligands  and 
drug-delivery functionalities. The surfaces of QDs can 
be modified for water solubility and biocompatibility, 
and  bioconjugation.  Many  efforts  have  been  under-
taken  to  investigate  ligand-receptor  interactions  by 
utilizing QD conjugated ligands including antibodies 
and peptides to target receptors such as growth factor Theranostics 2011, 1 
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receptors, integrins, and G-protein coupled receptors. 
Several groups have used QD-peptide complexes to 
target integrins to study the distribution of integrins 
on cell surfaces. Multiple copies of small peptide lig-
ands  can  be  easily  attached  to  the  QDs  by  bio-
tin-streptavidin interactions or direct covalent label-
ing of precoated QDs. 
Cai et al. reported the first RGD peptide-labeled 
QDs,  i.e.  QD705-RGD  for  targeting  and  imaging  of 
integrin  αvβ3-positive  tumor  vasculature  (Fig.  15) 
[73].  QD705-RGD  was  synthesized  from  a  commer-
cially  available  amine-containing  QD705  (emission 
maximum, 705 nm) which was first transformed to its 
maleimide intermediate (maleimide-QD705) and then 
reacted with a thiolated integrin αvβ3 antagonist RGD 
peptide,  c(RGDyK  (є-thiol))  (RGD-SH).  The  final 
QD705-RGD was estimated to have 30-50 RGD pep-
tides  per  QD  with  a  ligand  coupling  efficiency  of 
40-50%. As revealed by atomic force microscopy, the 
product  had  discrete  entities  with  smooth  and  uni-
form surface features, vertical heights of 5-7 nm, and 
lateral sizes of 15-20 nm, indicating that the structures 
were  single  QD  particles  without  aggregation. 
QD705-RGD  had  binding  with  integrin-positive 
MDA-MB-435 and U87MG cells with strong fluores-
cence signals which was blocked by 2 μM c(RGDyK), 
but  did  not  bind  to  integrin  αvβ3-negative  MCF-7 
cells  (human  breast  cancer  cell  line).  QD705-RGD 
showed high binding to the U87MG tumor tissue but 
no binding to the MCF-7 tumor tissue ex vivo. In vivo 
distribution and imaging studies of QD705-RGD were 
performed  in  athymic  nude  mice  bearing  U87MG 
tumors on their shoulders (tumor size, 0.5-0.8 cm3).  
 
 
 
Figure 15. c(RGDyK) functionalized QDs targeted to U87MG tumor tissues in vitro and in vivo. (A) Frozen U87MG tumor 
tissue staining using 50 nM QD705 (control experiment) and QD705-RGD. (B) In vivo NIR fluorescence imaging of U87MG 
tumor bearing mice injected with 200 pmol of QD705 (left) and QD705-RGD (right), respectively. Images were taken at 6 
h after injection. Adapted with permission from [73]. 
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Fluorescence  signal  of  QD705-RGD  was  ob-
served in the tumor as early as 20 min after i.v. injec-
tion (200 pmol of QD705-RGD, 6-10 nmol of peptide). 
The tumor signal intensity reached a maximum at 6 h. 
The tumor/background ratios (n = 3) were 3.08 ± 1.42, 
3.39 ± 1.13, 4.42 ± 1.88, and 2.09 ± 1.17 at 1, 4, 6, and 27 
h after injection, respectively. No significant fluores-
cent  signal  was  observed  in  the  tumor  at  all  time 
points after i.v. injection of QD705. After mice were 
euthanized  6  h  postinjection,  the  U87MG  tumors 
harvested  mice  showed  clear  signal  intensity  from 
QD705-RGD, but no signal was observed in tumors 
from QD705 mice. The signals from the QD705-RGD 
tumors  were  heterogeneous  and  were  mainly  from 
the tumor vasculature. Microscopic studies on tumor 
cryosections confirmed that QD705-RGD were in the 
tumor vasculature without tumor extravasation. This 
work provided the first example of RGD-bearing QDs 
for in vivo targeting and optical imaging of integrin 
positive tumor vasculature in a mouse model. 
 
 
 
 
Figure 16. Schematic structure of integrin targeting par-
amagnetic quantum dots.  
 
 
Mulder  et  al.  reported  a  novel  αvβ3-specific 
quantum dot-based nanoparticle, which has been op-
timized for both optical and magnetic resonance de-
tection of tumor angiogenesis [74]. The nanoparticu-
late contrast agent (Fig. 16) consists of a quantum dot 
core  covered  by  a  micellar  shell  composed  of 
pegylated  phospholipid  (PEG-DSPE)  and 
Gd-DTPA-based lipids (Gd-DTPA-BSA), of which the 
latter have paramagnetic properties for MRI. Cyclic 
RGD peptide  molecules  were conjugated to the na-
noparticles. Upon intravenous injection of RGD-pQDs 
in tumor-bearing mice, intravital microscopy allowed 
the detection of angiogenically activated endothelium 
at cellular resolution with a small scanning window 
and limited penetration depth, while magnetic reso-
nance imaging was used to visualize angiogenesis at 
anatomical  resolution  throughout  the  entire  tumor. 
Fluorescence imaging allowed whole-body investiga-
tion of angiogenic activity. Using these quantum dots 
and the aforementioned imaging modalities, the an-
giogenic tumor vasculature was readily detected with 
the  highest  angiogenic  activity  occurring  in  the  pe-
riphery of the tumor.  
This  nanoparticle  may  be  employed  for  multi-
modality imaging of a variety of diseases that are ac-
companied  by  activation  of  endothelial  cells.  Fur-
thermore, the current technology might be developed 
for  molecular  imaging  of  other  pathophysiological 
processes. 
Integrin  αvβ3-Targeted  PAMAM  Dendrimers  Pol-
yamidoamine  (PAMAM)  dendrimers  have  received 
considerable attention for their potential biomedical 
applications since their introduction by Tomalia and 
co-workers in 1985. PAMAM bearing chelated gado-
linium  (Gd(III))  serve  as  a  novel  class  of  magnetic 
resonance imaging (MRI) contrast agents of high mo-
lar relaxivities and superb image enhancement. Bos-
well  et  al.  reported  that  the  synthesis,  characteriza-
tion, and biological evaluation of robust multimodal 
integrin  αvβ3-targeted  PAMAM  dendrimers  with 
fluorescent dyes for optical imaging and chelates for 
gadolinium-based magnetic resonance (MR) imaging 
of tumor angiogenesis (Fig. 17) [75]. Fluorescence mi-
croscopy revealed selective binding  of the resulting 
RGD peptide-bearing dendrimer with empty chelates 
to integrin αvβ3-expressing M21 cells, but somewhat 
reduced  selectivity  was  observed  following  Gd(III) 
complexation. The expected incomplete saturation of 
chelates with Gd(III) ions permitted radiometal com-
plexation,  The  RGD  peptide-bearing  gadomer  was 
also labeled with 111In using available empty chelates, 
and an in vivo tissue distribution of the resulting agent 
in M21 melanoma tumor-bearing mice showed mostly 
renal and reticuloendothelial accumulation. An in vivo 
tissue  distribution  study  in  tumor-bearing  mice 
showed disappointingly little tumor accumulation. 
Silica nanoparticles as a platform for multimodality 
imaging  Nanoparticles  that  allow  combined  fluores-
cence  imaging  and  MRI  are  probably  the  most  fre-
quently studied because they unite the high sensitiv-
ity  of  the  fluorescence  phenomenon  with  the  high 
spatial resolution of MRI. Silica nanoparticles can be 
used as carriers for a wide range of substances and 
have received considerable attention for their poten-
tial  biomedical  applications.  Koole  et  al.  reported  a Theranostics 2011, 1 
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novel  method  for  creating  biocompatible  and  tar-
get-specific silica particles coated with a dense mon-
olayer of paramagnetic and PEGylated lipids to im-
prove  circulation  time  and  the  biocompatibility  for 
both MRI and fluorescence imaging (Fig. 18) [76-77]. 
The silica nanoparticles having a quantum dot in their 
center were made target-specific by the conjugation of 
multiple RGD peptides. A highly monodisperse, flu-
orescent, and paramagnetic contrast agent suitable for 
both fluorescence imaging and MRI studies was ob-
tained.  Their  specific  uptake  was  demonstrated  by 
endothelial  cells  in  vitro  using  fluorescence  micros-
copy, quantitative fluorescence imaging and magnetic 
resonance imaging. Such lipid coated silica particles 
represent a new platform for nanoparticulate multi-
modality contrast agents. 
 
 
 
 
 
Figure 17. Schematic structure of integrin αvβ3-targeted PAMAM dendrimer carrying both fluorescent dyes and Gd 
chelates.  
 Theranostics 2011, 1 
 
http://www.thno.org 
122 
 
Figure 18. Silica nanoparticles containing QD in the core and PEGylated lipid and paramagnetic lipid coating.  
 
Integrin-targeted  optical  imaging  by  other  methods 
Over the past years, some new optical imaging tech-
niques  have  been  developed  such  as  fluores-
cence-mediated  tomography,  diffuse  optical  tomog-
raphy,  and  two  photon  microscopic  imaging,  and 
fluorescence life time measurement [78,79]. They offer 
a range of new capabilities for molecular imaging to 
enhance  biomedical  studies.  Correspondingly,  they 
have exerted significant impacts on the construction 
and evaluation of new optical agents. 
As described above, von  Wallbrunn et al. used 
FMT to study a Cy5.5-labeled disulfide-based cyclic 
RGD peptide for optical imaging of integrin αvβ3 ex-
pression  [63].  Compared  to  two-dimensional  planar 
fluorescence reflectance imaging (FRI), FMT allowed 
quantification  of  the  fluorochrome  distribution  in 
deeper tissue sections. FMT can provide more accu-
rate,  sensitive,  specific,  quantitative, 
three-dimensional imaging information and has great 
potential  for  clinical  applications.  Moreover,  recent 
technical advances suggest that cross-sectional optical 
imaging techniques may be applied not only experi-
mentally but also for patient care (e.g. optical mam-
mography) and may therefore significantly enhance 
the  sensitivity  and  specificity  of  diagnostic  proce-
dures. RGD-Cy5.5 combined with novel tomographic 
optical imaging methods allows non-invasive imag-
ing of tumor-associated αvβ3 expression and may thus 
be  a  promising  strategy  for  sensitive  evaluation  of 
tumor target expression. 
Local molecular and physiological processes can 
be imaged in vivo through perturbations in the fluo-
rescence lifetime (FLT) of optical imaging agents. In 
addition  to  providing  functional  information,  FLT 
methods can quantify specific molecular events and 
multiplex  diagnostic  and  prognostic  information. 
Northdurft et al. reported a fluorescence lifetime dif-
fuse optical tomography (DOT) system (FLT-DOT) for 
in vivo preclinical imaging [79]. By using differential 
phase measurements, they demonstrate DOT imaging 
of short lifetimes (from 350 ps) with high precision 
(+/-5  ps).  Furthermore,  this  system  retains  the  effi-Theranostics 2011, 1 
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ciency, speed, and flexibility of transmission geome-
try DOT. They used this method to successfully visu-
alize  the  uptake  of  a  near-infrared  (NIR)  fluores-
cent-labeled peptide probe i.e. cypate-RGD by a sub-
cutaneous tumor in a mouse model. 
Smith et al. used intravital microscope with sub-
cellular  (approximately  0.5  microm)  resolution  to 
further study the interactions of the RGD-conjugated 
QDs  with  tumor  neovasculature  in  living  mouse 
models.  For  the  first  time,  the  binding  of  such 
RGD-nanoparticle conjugates to tumor blood vessels 
in living was visualized and recorded. The nanopar-
ticles were also found to bind in aggregation forms 
without extravasation [80].  
Multiphoton fluorescence microscopy is a pow-
erful tool for biological imaging and for the study of 
dynamic processes in living cells. This application is 
dependent on the development of highly fluorescent, 
water-soluble,  photochemically  stable,  multiphoton 
absorbing  chromophores.  Most  known  fluorescent 
probes that can be utilized in one-photon fluorescence 
bioimaging are not optimized for two-photon excita-
tion. Morales et al. reported the synthesis and identi-
fication  of  a  new  fluorene  derivative, 
3-(9-(2-(2-methoxyethoxy)ethyl)-2,7-bis{3-[2-(polyeth
yleneglycol-550-monomethylether-1-yl)]-4-(benzo[d] 
thiazol-2-yl)styryl}-9H-fluoren-9-yl)propanoic  acid 
[81].  Comprehensive  spectral  analysis  of  the  linear 
and  nonlinear  optical  properties  of  this  new  wa-
ter-soluble  fluorenyl  derivative,  along  with  its  high 
fluorescence  quantum  yield  and  photochemical  sta-
bility, makes this compound an intriguing candidate 
for use as a fluorescence probe. Its RGD conjugate was 
incubated with U87MG cells (and MCF-7 as control) 
and exhibited high integrin αvβ3 selectivity in both 
conventional  (one-photon)  and  two-photon  fluores-
cence microscopy imaging.  
Photodynamic therapy (PDT) provides an alter-
native  approach  for  cancer  therapy  in  the  clinic. 
Tetrapyrrol chromophores, such as porphyrins, chlo-
rins,  benzochlorins,  bacteriochlorin  and  phthalocya-
nines,  are  well-known  photosensitizers.  They  can 
generate  singlet  oxygen  and  radicals  from  their 
long-lived triplet excited states to initiate cellular tox-
icity events. Many tetrapyrroles have red-shifted ab-
sorption  and  reasonable  fluorescence  emission  (life-
time ~ 10 ns), making them applicable for diagnostic 
purposes.  Photosensitisers  generally  have  little  in-
trinsic selectivity for tumors and any accumulation is 
dependent upon the type of tumor involved. Integ-
rin-targeted delivery has also provided a way for in-
creasing  tumor  selective  accumulation  of  a  PDT  to 
reduce any risk of side effects caused by photosensi-
tiser accumulation in non-target tissue and improving 
the therapeutic efficacy of PDT agents potentially. As 
reported  by  Conway  et  al.  [3],  protoporphyrin  IX 
(PpIX)  was  conjugated  with  cyclic  RGDfK  peptide 
(Fig.  19).  It  retained  their  respective  photodynamic 
and integrin binding activity. The PpIX:cRGDfK con-
jugate is shown to be a good photosensitiser in vitro in 
the integrin positive human SiHa cell line and in vivo 
in a mouse CaNT tumor model. Moreover, pharma-
cokinetic  analysis  of  PpIX:cRGDfK  treated  mice 
showed  significant  retention  and  accumulation  of 
photosensitizer in tumor tissue with higher tumor : 
normal  tissue  ratios  than  the  free  photosensitizer. 
However,  the  overall  in  vivo  PDT  effect,  between 
dose-light intervals of 0 and 6 h, is not significantly 
better than the free protoporphyrin IX. This is possi-
bly due to differences in the target environment or in 
the subcellular localisation of the compounds.  
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Figure  19.  Schematic structure of PpIX:cRGDfK conju-
gate.  
 
4. Conclusions and Perspectives 
Integrin receptors serve as attractive targets for 
both molecular imaging and therapy. Some promising 
data from preclinical and clinical studies demonstrate 
the applications of their ligands as vectors for targeted 
delivery  of  anticancer  agents  and  imaging  agents 
[82-84]. As summarized above, various types of opti-
cal probes based on RGD-containing small molecules 
and  fluorescent  nanoparticles  have  been  designed, 
synthesized and evaluated for tumor optical imaging. 
The high specificity and sensitivity of some integrin 
targeted  probes  for  tumor  optical  imaging  in  tu-
mor-bearing  mouse  models  demonstrate  the  great 
potential of integrin targeting in cancer imaging and 
targeted  therapy.  All  these  results  have  further 
deepened our understanding of integrin receptor ex-
pression in tumor  targeting and imaging. These in-
tegrin-targeted  optical  agents  can  become  valuable 
tools for studying integrin receptors and related sig-Theranostics 2011, 1 
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naling transduction in cancer biology. It is important 
to  further  explore  their  potential  by  studying  their 
toxicity, and pharmacokinetics as well as tumor im-
aging  specificity  and  selectivity  in  different  models 
for translational studies and final regulatory approv-
als.  
The above examples illustrate the great potential 
of  optical  imaging  technologies  in  oncologic  drug 
discovery and development. As reported previously, 
integrin antagonists such as cyclic RGD peptide ana-
logs are potential anticancer agents due to their an-
ti-angiogenesis,  apoptotic  induction,  and  selective 
cytotoxicity.  They  can  also  serve  as  potential  integ-
rin-targeting vectors for drug delivery. Therefore, the 
integrin-targeted optical agents may serve as a novel 
type of theranostic agents for simultaneous molecular 
imaging and targeted therapy. The related in vivo op-
tical  imaging  can  provide  insights  into  the  rational 
design,  structural  optimization,  and  evaluation  of 
new integrin-targeted anticancer agents.  
Further work in the field will be expected to en-
large  the  scope  of  integrin-targeted  optical  imaging 
and  advance  both  the  fundamental  and  applied 
knowledge  in  different  aspects:  1)  new,  innovative 
optical probes with improved optical properties such 
as quantum yield, life time, photo-stabilities, and bi-
ocompatibilities;  2)  new  integrin-targeting  ligands 
including both peptides and peptidomimetics; 3) new 
integrin-targeted  multifunctional  optical  probes  in-
cluding both small molecules and nanoparticle-based 
compounds for integrating optical imaging with other 
imaging  and  therapy  modalities;  4)  new  integ-
rin-targeting  multifunctional  activatable  optical 
probes.  
Imaging methods used in the clinic are not per-
fect  to  warrant  complete  accurate  cancer  detection 
and  diagnosis.  Despite  the  drawback  of  optical  im-
aging in its limited tissue penetration, there have been 
some  successful  applications  in  the  clinic  such  as 
cancer detection, lymphatic imaging (sentinel lymph 
node  detection),  surgical/endoscopic  guidance,  and 
optical mammography. This is because optical imag-
ing can complement some other imaging methods to 
some extent. With further development of  new tar-
geted  optical  agents,  techniques  and  instrumenta-
tions, optical imaging is expected to play increasingly 
important  roles  in  clinical  cancer  imaging.  Conse-
quently,  all  these  will  lead  to  the  improvements  of 
cancer imaging, therapy, and even prevention. 
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